Myriad myPath™ Melanoma Improves Diagnosis And Treatment Plans


Myriad myPath Melanoma improves the diagnosis and treatment  plans of melanoma.
Myriad myPath Melanoma improves the diagnosis and treatment
plans of melanoma. (Image source)
Myriad Genetics, Inc. today presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a genetic test that differentiates malignant melanoma from benign skin lesions across all major melanoma subtypes. Key findings of this clinical utility study included a 43 percent reduction in indeterminate diagnoses and a 49 percent change in physicians' treatment recommendations for patients.
 
The study evaluated the impact of the Myriad myPath Melanoma diagnostic test on dermatopathologists' diagnoses and intended treatment recommendations for 218 patients with pigmented skin lesions that were considered difficult to diagnose. The dermatopathologists recorded their diagnoses and treatment plans before and after receiving the myPath Melanoma test results. The changes in patient diagnoses are summarized in the table below.
 
Pathology Diagnosis Pre-Test (N=218)Post-Test (N=218) % Change
Benign 10.6% 40.8% +30.2%
Malignant9.2%21.6% +12.4%
Indeterminate 80.3%37.6% - 42.7%

The dermatopathologists were also asked how the Myriad myPath Melanoma test result would change their intended treatment recommendations for patients. Overall, changes in treatment recommendations were observed in 49.1 percent of difficult-to-diagnose cases. In 39.4 percent of patients receiving a benign test result, recommendations were downgraded to less invasive treatment. Conversely, in 45.8 percent of patients receiving a malignant test result, recommendations were upgraded to more invasive treatment.

The Myriad myPath Melanoma test objectively answers a vital clinical question for physicians: "Does my patient have malignant melanoma that requires aggressive intervention, or a harmless skin lesion that should be monitored?"